Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology ...
AUSTIN, TX--(Marketwired - February 16, 2018) - Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today reported that top line results from the multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of Aironite, a …